EML4 and neoplasm: In a previous matched tissue-blood analysis, 21% of ALK-positive non-small cell lung cancer patients showed multiple tumor-specific EML4::ALK variants,35 indicating the existence of fusion-defined tumor heterogeneity evident at the genomic level.